Research & Initiatives
EpiFocus is in the forefront of organomic discoveries, employing novel analytical techniques to signals recorded from multiple organ systems to provide quantitative feedback to physicians
EpiFocus' origin is connected with multiple success stories in epilepsy research. In particular, the company's founders have been big in the fields of prediction of seizures long time (minutes to hours) before they occur, ability to daily assess the patient's susceptibility to seizures, closed-loop control of brain's pathology by timely external intervention so that seizures would not have to occur to reset that pathology (seizure control), as well as localization of the epileptogenic focus in patients with medically refractory focal epilepsy without the need of seizures to occur. While the original goals were to reduce patient discomfort and increase the accuracy of resective surgery and efficacy of neuromodulation treatment frameworks, we have further expanded our work to acute and extreme conditions in epilepsy and other brain dynamical disorders, as well as other disease states.
​
By application of novel signal processing and multi-organ systems analysis techniques, we have developed data-driven metrics for assessment of risk to Sudden Unexpected Death in Epilepsy (SUDEP), and biomarkers for monitoring the treatment and recovery from Status Epilepticus (SE). Examples of application of our methods to a wide spectrum of diseases, that may concurrently affect neuronal, cardiac, and respiratory systems, include the monitoring and treatment of traumatic brain injury (TBI), stroke and cardiovascular crises, electroconvulsive treatment (ECT) of depression, and diabetes.